Claris Ventures, €85 Million Closing for the Turin-based Sgr Focused on Early-Stage Biotech

Claris Ventures Sgr has announced the closing of subscriptions for the “Claris Biotech I” fund and the “Claris Biotech I – Parallel fund”, for a total of $100 million (€85 million). As stated in a note, the capital raised will be invested primarily in new Italian biotech companies engaged in the development of drugs for the treatment of diseases with high clinical needs.

The final closing sees the entry of the European Investment Fund (EIF), with a subscription of $47 million (€40 million), and a further subscription of $11.7 million (€10 million) by CDP Venture Capital on behalf of the Mise Co-investment Fund, which follows previous subscriptions by CDP Venture Capital on behalf of FOF VenturItaly, Fondazione Compagnia di San Paolo, Inarcassa, Ersel, and other private individuals and family offices.

If you want to find more details about Claris Ventures and its closing of subscriptions for “Claris Biotech I” fund and the “Claris Biotech I – Parallel fund”, for a total of $100 million (€85 million), download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the latest finance news in the world and the most important market updates.

Comments on the operation

“The importance of early-stage initiatives in biotech can easily be underestimated. It is our job to ensure that the necessary capital is available so that technologies that can change our lives can reach their full potential,” commented Alessandro Tappi, director of Fei.

“We enthusiastically renew our trust in Claris Ventures, which supports the birth and growth of Italian biotech companies, now more than ever at the center of national and international interest,” said Enrico Resmini, managing director and general manager of Cdp Venture Capital Sgr.

The commitment of Claris Ventures

Claris Ventures, founded by Pietro Puglisi and Ciro Spedaliere, is thus confirmed as one of the main Italian operators with a focus on early-stage biotech, a sector of strategic importance for the country. “The trust placed in Claris Ventures by important national and international institutions allows us to contribute decisively to the development of the Italian biotech sector, creating a positive impact on patients and generating economic and social value at the same time,” commented Puglisi and Spedaliere.

Two investments are already in the portfolio, one in the immuno-oncology field and the other in the metabolic field. The investment rounds in the first two companies, for a total of $28 million (€24 million), were led by Claris Ventures as lead investor and saw the participation of international investors and pharmaceutical companies.

__

(Featured image by Visual Stories via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.